Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth

Vaccine

Volumn 29, Issue 33, 2011, Pages 5534-5543

  Guillot, Flora ^a,b   Boutin, Benoît ^a,b   Blanquart, Christophe ^a,b   Fonteneau, Jean François ^a,b   Robard, Myriam ^b   Grégoire, Marc ^a,b   Pouliquen, Daniel ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Epigenetic drug; Immunisation; Mesothelioma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CURCUMIN; SELENITE; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; EPIGENETICS; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; OMENTUM; PANCREAS; PERITONEAL CAVITY; PERITONEUM CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; VACCINATION;

EID: 79960364764     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.029     Document Type: Article

References (43)

1. Robinson B.W.S., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
2. Ryan C.W., Herndon J., Vogelzang N.J. A review of chemotherapy trials for malignant mesothelioma. Chest 1998, 113:S66-S73.
3. Reck M., Gatzemeier U. Pemetrexed-cisplatin combination in mesothelioma. Expert Rev Anticanc Ther 2005, 5:231-237.
4. Lu D., Hoory T., Monie A., Wu A., Wang M.-C., hung C.-F. Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009, 27:4363-4369.
5. Sigalotti L., Coral S., Altomonte M., Natali L., Gaudino G., Cacciotti P., et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002, 86:979-982.
6. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
7. Vandermeers F., Hubert P., Delvenne P., Mascaux C., Grigoriu B., Burny A., et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15:2818-2828.
8. Robinson B.W.S., Robinson C., Lake R.A. Localised spontaneous regression in mesothelioma - possible immunological mechanism. Lung Cancer 2001, 32:197-201.
9. Robinson C., Robinson B.W.S., Lake R.A. Sera from patients with mesothelioma can contain autoantibodies. Lung Cancer 1998, 20:175-184.
10. Boisteau O., Gautier F., Cordel S., Henry F., Harb J., Douillard J.Y., et al. Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997, 2:403-412.
11. Ebstein F., Sapede C., Royer P.-J., Marcq M., Ligeza-Poisson C., Barbieux I., et al. cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells. Am J Respir Crit Care Med 2004, 169:1322-1330.
12. Hegmans J.P., Hemmes A., Aerts J.G., Hoogsteden H.C., Lambrecht B.N. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005, 171:1168-1177.
13. Hegmans J.P., Veltman J.D., Lambers M.E., de Vries I.J.M., Figdor C.G., Hendriks R.W., et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Resp Crit Care Med 2010, 181:1383-1390.
14. Grégoire M., Ligeza-Poisson C., Juge-Morineau N., Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 2003, 21:791-794.
15. Chiang C.L., Benencia F., Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010, 22:132-143.
16. Moalli P.A., MacDonald J.L., Goodglick L.A., Kane A.B. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am J Pathol 1987, 128:426-445.
17. Grange J.M., Botasso O., Stanford C.A., Stanford J.L. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008, 26:4984-4990.
18. Liu T., Kuljaca S., Tee A., Marshall G.M. Histone deacetylase inhibitors: multifonctional anticancer agents. Cancer Treat Rev 2006, 32:157-165.
19. Krug L.M., Curley T., Schwartz L., Richardson S., Marks P., Chiao J., et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7:257-261.
20. Marks P.A., Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005, 4:549-551.
21. Pillai G.R., Srivastava A.S., Hassanein T.I., Chauhan D.P., Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 2004, 208:163-170.
22. Aggarwal B.B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007, 595:1-75.
23. Nilsonne G., Sun X., Nyström C., Rundlöf A.-K., Fernandes A.P., Björnstedt M., et al. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 2006, 41:874-885.
24. Rundlöf A.-K., Fernandes A.P., Selenius M., Babic M., Shariatgorji M., Nilsonne G., et al. Quantification of alternative mRNA species and identification of thioredoxine reductase 1 isoforms in human tumor cells. Differenciation 2007, 75:123-132.
25. Copier J., Ward S., Dalgleish A. Cell based cancer vaccines: Regulatory and commercial development. Vaccine 2007, 25S:B35-B46.
26. Means T.K., Wang S., Lien E., Yoshimura A., Golenbock D.T., Fenton M.J. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999, 163:3920-3927.
27. Akazawa T., Masuda H., Saeki Y., Matsumoto M., Takeda K., Tsujimura K., et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 2004, 64:757-764.
28. Hanna M.G., Peters L.C. Immunotherapy of established micrometastases with Bacillus Calmette-Guerin tumor cell vaccine. Cancer Res 1978, 38:204-209.
29. Hayashi A., Doi O., Azuma I., Toyoshima K. Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patient. Proc Jpn Acad 1998, 74:50-55.
30. Uyl-de Groot C.A., Vermorken J.B., Hanna MGJr, Verboom P., Groot M.T., Bonsel G.J., et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005, 2379-2387.
31. Rangel-Moreno J., Moyron-Quiroz J.E., Carragher D.M., Kusser K., Hartson L., Moquin A., et al. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity 2009, 30:731-743.
32. Gerber S.A., Rybalko V.Y., Bigelow C.E., Lugade A.A., Foster T.H., Frelinger J.G., et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006, 169:1739-1752.
33. Lawrance R.J., Loizidou M., Cooper A.J., Alexander P., Taylor I. Importance of the omentum in the development of intra-abdominal metastases. Br J Surg 1991, 78:117-119.
34. Krist L.F., Eestermans I.L., Steenbergen J.J., Hoefsmit E.C., Cuesta M.A., Meyer S., et al. Cellular composition of milky spots in the human greater omentum: an immunochemical and ultrastructural study. Anat Rec 1995, 241:163-174.
35. Krist L.F., Kerremans M., Broekhuis-Fluitsma D.M., Eestermans I.L., Meyer S., Beelen R.H. Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother 1998, 47:205-212.
36. Beelen R.H. The greater omentum: physiology and immunological concepts. Neth J Surg 1991, 43:145-149.
37. Cordier Kellerman L., Valeyrie L., Fernandez N., Opolon P., Sabourin J.-C., Maubec E., et al. Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. Cancer Gene Ther 2003, 10:481-490.
38. Woo E., Chu C., Goletz T., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumours from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
39. Pouliquen D.L. Hepatic mitochondrial function and brain tumours. Curr Opin Clin Nutr Metab Care 2007, 10:475-479.
40. Finke J., Ferrone S., Frey A., Mufson A., Ochoa A. Where have the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999, 20:158-160.
41. Homo-Delarche F., Drexhage H.A. Immune cells, pancreas development, regeneration and type 1 diabetes. Trends Immunol 2004, 25:222-229.
42. Jansen A., Homo-Delarche F., Hooijkaas H., Leenen P.J., Dardenne M., Drexhage H.A. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 1994, 43:667-675.
43. Junger E., Herberg L., Jeruschke K., Leiter E.H. The diabetes-prone NZ0/HI strain. II. Pancreatic immunopathology. Lab Invest 2002, 82:843-853.